Treprostinil 20 MG/ML Injectable Solution [Remodulin] — RxCUI 2590177
RxNorm drug concept · Semantic branded drug
RxCUI 2590177
Semantic branded drug · SBD
Retired or remapped concept 6 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2590177
Official nameTreprostinil 20 MG/ML Injectable Solution [Remodulin]
Concept typeSemantic branded drug (SBD)
RxNorm statusRetired or remapped concept
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)7,471 prescriptions · 35 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Treprostinil: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Treprostinil mimics a natural substance your body makes to keep blood vessel walls relaxed. In pulmonary arterial hypertension (PAH) — and in some lung-disease-related forms of hig...
- What exactly is treprostinil and why did my doctor prescribe it?
- The inhaled products are all used multiple times per day, spaced out across your waking hours. Tyvaso and Tyvaso DPI are typically used 4 times a day, roughly 4 hours apart. Yutrep...
- I'm on the inhaled version — how often do I need to use it each day?
🕸️ Concept Web
No related-concept groups were available for this RxCUI in the loaded RxNorm data. That does not prove that no related concepts exist.
📦 FDA Products & Package NDCs
6 products · 6 package NDCs
6 package NDCs map to RxCUI 2590177 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 66302-0101-01 | 1 VIAL in 1 BOX (66302-101-01) / 20 mL in 1 VIAL | Remodulin | United Therapeutics Corporation | 2002-05-22 |
| 66302-0102-01 | 1 VIAL in 1 BOX (66302-102-01) / 20 mL in 1 VIAL | Remodulin | United Therapeutics Corporation | 2002-05-22 |
| 66302-0105-01 | 1 VIAL in 1 BOX (66302-105-01) / 20 mL in 1 VIAL | Remodulin | United Therapeutics Corporation | 2002-05-22 |
| 66302-0110-01 | 1 VIAL in 1 BOX (66302-110-01) / 20 mL in 1 VIAL | Remodulin | United Therapeutics Corporation | 2002-05-22 |
| 66302-0114-01 | 1 VIAL in 1 BOX (66302-114-01) / 20 mL in 1 VIAL | Remodulin | United Therapeutics Corporation | 2023-09-28 |
| 66302-0150-50 | 1 VIAL in 1 BOX (66302-150-50) / 50 mL in 1 VIAL | Sterile Diluent for Remodulin | United Therapeutics Corporation | 2014-12-22 |
Observed labelers:
United Therapeutics Corporation (6)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J3285 | Treprostinil injection | 5 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.